Our research line focus on avian viral hepatitis, although the human viral hepatitis research community has a great research interest on this topic, as its strong nexus to acute hepatitis and chronical hepatitis, cirrhosis and liver cancer. However, certain similar diseases that is highly prevalent in duckling or mature ducks was not well-recognized. The mission of our study is to prevent and control epidemic of avian viral hepatitis, especially infection caused by duck hepatitis A virus (DHAV). Because infection by the DHAV is highly fatal and their prevalence in China is currently high, in particular genotype 1 and genotype 3. To do so, multidisciplinary knowledge has been integrated to better understand viral pathogenesis, viral functional proteomics (i.e., 3C), virus-host interactions upon infection by DHAV and other relevant hepatitis viruses. We hope that our research will add new mechanistical perception of avian viral hepatitis, thus may completely prevent or eliminate this disease by exploiting novel vaccine technologies, new measures or drugs from basic research. With three decades of effort, Prof. Anchun Cheng, the founder of our faculty, has successfully developed a live attenuated DHAV vaccine (genotype 1) and now widely applied in duck industry. Other bio-pharmacal agents including egg yolk immunoglobulins has been developed and show considerable clinical benefit in infected ducklings. Followed by this direction, three youth scientists were joined and continued to focus on the avian viral hepatitis. Until September 2022, we have contributed to 35 SCI-cited publications which most of them are published in TOP ranked journals in veterinary fields. These publications were funded by both "13th Five-Year" National Key Research and Development Plan project, national scientific research project of Sichuan province, and NSFC grants. Let’s do science corporately and try to vanish it.